BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if BHT-3009 decreases inflammation (measured by
gadolinium enhancing MRI lesions) in the brains of people with relapsing remitting multiple
sclerosis.